Merck & Company Inc (MRK)vsNewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
$22.80
+4.30%
HEALTHCARE · Cap: $2.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 934727% more annual revenue ($66.57B vs $7.12M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
NAMS
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for NAMS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -32.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NAMS
The strongest argument for NAMS centers on Debt/Equity, Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NAMS
The primary concerns for NAMS are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →NewAmsterdam Pharma Company N.V. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address critical unmet medical needs. With an advanced clinical development pipeline and a strategic commitment to reshaping treatment approaches, the company stands poised to significantly influence the healthcare landscape. Guided by a seasoned management team, NewAmsterdam offers a compelling investment opportunity for institutional investors aimed at facilitating transformative healthcare solutions that enhance patient outcomes while ensuring sustainable growth in the biopharmaceutical arena.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?